Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
Ankith Mohan(Center for Biologics Evaluation and Research), M. Miles Braun(Center for Biologics Evaluation and Research), Augustine Manadan(Rush University Medical Center), Joel A. Block(Rush University Medical Center), Ronald Timothy(Center for Biologics Evaluation and Research), Jeffrey Siegel(Center for Drug Evaluation and Research)
Cited by 304
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448